Vitality Watch

Dossier pubmed preclinical 18-jul-2026
Animal model, organoid, or cell-culture result — not yet human

Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma.

Key claim: Gemcitabine-induced tumor-cell senescence stiffens PDAC stroma via SASP and Piezo1, driving BRG1–NRF2–SLC7A11 antioxidant programs that suppress ferroptosis and confer chemoresistance, which ABT-263 plus Erastin can reverse in vivo.

Abstract

Chemoresistance in pancreatic ductal adenocarcinoma (PDAC) is partly driven by pathological stromal remodeling, yet the underlying mechanisms remain poorly understood. Here, we show that gemcitabine treatment induces tumor cell senescence and activates cancer-associated fibroblasts via the senescence-associated secretory phenotype, leading to progressive fibrotic matrix stiffening. This biomechanical reprogramming engages the mechanosensitive ion channel Piezo1, triggering metabolic rewiring that renders BRG1-positive tumor cells increasingly dependent on NRF2-mediated antioxidant defenses. Piezo1 signaling promotes NRF2 nuclear translocation and its chromatin-remodeling cooperation with BRG1, thereby upregulating SLC7A11-dependent antioxidant programs and suppressing ferroptosis. Notably, the combination of the senolytic agent ABT-263 with the ferroptosis inducer Erastin effectively dismantles BRG1-NRF2-driven gemcitabine resistance, alleviates stromal fibrosis, enhances T-cell infiltration, and suppresses tumor growth in vivo. This senolytic-ferroptosis approach exploits metabolic vulnerabilities in chemotherapy-aged PDAC and provides a mechanistic rationale for stroma-targeted combination therapies.

Why this matters

This finding adds a concrete molecular circuit — Piezo1-sensed stromal stiffening feeding a BRG1–NRF2–SLC7A11 antioxidant program — that explains how senescent cells can actively suppress ferroptosis, linking two mechanisms usually catalogued separately in aging biology. It also supplies a preclinical rationale for pairing senolytics with ferroptosis inducers, though the context is chemoresistant pancreatic cancer rather than healthspan, so translation to aging interventions remains speculative.

Source

Link

Briefing card

Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma.
Stage: preclinical · pubmed · 18-jul-2026

Gemcitabine-induced tumor-cell senescence stiffens PDAC stroma via SASP and Piezo1, driving BRG1–NRF2–SLC7A11 antioxidant programs that suppress ferroptosis and confer chemoresistance, which ABT-263 plus Erastin can reverse in vivo.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1038/s41467-026-75772-5

build build 880 · 2bcef25 · 2026-11-18